BUZZ-遗传性疾病药物晚期试验失败,Harmony 公司业绩下滑

路透中文
Sep 24
BUZZ-遗传性疾病药物晚期试验失败,Harmony 公司业绩下滑

9月24日 - ** 药物开发商和谐生物HRMY.O股价盘前下跌6.6%,至29.94美元

** 该公司称其试验性药物ZYN002在脆性X综合征患者的晚期试验中没有达到 (link)。

** 脆性 X 综合征$(FXS)$ 是一种遗传性疾病,也是导致遗传性智力障碍的最常见原因之一。

** HRMY称,该药物没有达到改善社交回避的主要目标,主要原因是安慰剂反应率高于预期

** 截至上次收盘,股价累计下跌 6.8

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10